Specific Diabetic Drug is Now Safe for Cancer Patients With Kidney Concerns
Contrary to concerns, GLP-1RA medications don�t appear to elevate AKI risk in patients undergoing cancer treatment.
New research indicates that GLP-1 receptor agonists (GLP-1RA), widely used for type 2 diabetes and heart failure, do not increase the risk of acute kidney injury (AKI) in patients on anti-cancer therapies, to be presented at ASN Kidney Week 2024 October 23- 27().
This finding clarifies earlier concerns about AKI risks associated with GLP-1RA usage in these patients. For the study, investigators analyzed medical records of patients who were treated with anti-cancer medications including cytotoxic, targeted immunotherapies over 1 year.
‘ Did You Know?
Acute kidney injury affects up to 20% of hospitalized patients worldwide. #diabetes #acutekidneyinjury ’
Reassuring Findings for Cancer Patients
Among 14,783 patients, 9% were treated with a GLP-1RA while taking ant-cancer drugs. AKI occurred in 7.2% of those exposed to GLP-1RA versus 6.4% of those with no GLP-1RA exposure."Given the cardiovascular and anti-diabetic benefits of GLP-IRA, we suggest that these agents can be safely continued during the administration of anti-cancer therapy," said corresponding author Swetha Rani Kanduri, MD, of Ochsner Health.
"We invite prospective studies to further elaborate on the effects of GLP1-RA in patients with cancer."
Reference:
- ASN Kidney Week 2024 - (https:www.asn-online.org/education/kidneyweek/)
Source: Eurekalert